FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is front and center in a recent InvestmentPitch Media Video. The video spotlighted FDS Pharma’s recent submission of its clinical trial application for an upcoming phase a trial evaluating Lucid-MS. A candidate for treatment of multiple sclerosis (“MS”), Lucid-MS is a first-in-class neuroprotective compound featuring a novel mechanism action that has been shown to prevent myelin degradation, or demyelination, a significant cause of MS and other neurodegenerative diseases. According to the announcement, Lucid-MS is being developed by Lucid Psycheceuticals Inc., a wholly owned subsidiary of FSD Pharma. FSD Pharma is also working on developing two other drug candidates. InvestmentPitch Media specializes in producing short videos based on significant news releases, research reports and other content of interest to investors. “This is an exciting time for our company, shareholders, and most importantly for the MS community,” said Lucid Psycheceuticals CEO Dr. Lakshmi Kotra in the press release. “Multiple sclerosis is a debilitating disease without any cure, relegating patients and caregivers to significantly lower quality of life. There is an intense effort for disease-modifying treatments to address unmet needs especially for the treatment of progressive MS, and potentially that are nonimmunomodulatory. Lucid-MS is a promising first-in-class agent with a novel mechanism of action with a potential to address progressive stages of the disease. Lucid-MS is nonimmunomodulatory in its mechanisms of action based on current evidence. We are optimistic about the potential of Lucid-MS, and we are eager to initiate this clinical trial taking this one step closer to the patients.”
To view the video, visit https://ibn.fm/OxX10
To view the full press release, visit https://ibn.fm/tjEIz
About FSD Pharma Inc.
FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound FSD201, an ultramicronized palmitoyl ethylamine (“PEA”) for the treatment of inflammatory diseases. Lucid Psycheceuticals Inc. is a wholly owned subsidiary focused on the research and development of its lead compounds: Lucid-PSYCH and Lucid-MS. Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. For more information about the company, please visit www.FSDPharma.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.